(UBU7) UBS (Irl) - MSCI World - Overview
Etf: Stocks, Developed, Large, Mid, Cap
Dividends
| Dividend Yield | 1.65% |
| Yield on Cost 5y | 1.13% |
| Yield CAGR 5y | 17.70% |
| Payout Consistency | 95.5% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 12.8% |
| Relative Tail Risk | -3.58% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.07 |
| Alpha | -1.87 |
| Character TTM | |
|---|---|
| Beta | 0.200 |
| Beta Downside | 0.430 |
| Drawdowns 3y | |
|---|---|
| Max DD | 21.69% |
| CAGR/Max DD | 0.74 |
Description: UBU7 UBS (Irl) - MSCI World January 02, 2026
The MSCI World UCITS ETF (USD) A-dis EUR (XETRA: UBU7) is a Germany-domiciled, exchange-traded fund that tracks the Morningstar Global TME NR USD index. It belongs to the Global Large-Cap Blend Equity category and offers investors exposure to roughly 1,600 developed-market stocks across 23 countries, with a concentration in the United States (≈ 65 % of assets).
Key quantitative attributes (as of the latest public data, Q4 2024) include an expense ratio of 0.20 % and total assets under management of about €5 billion, placing it among the higher-liquidity MSCI World ETFs. The fund uses a physical replication strategy, distributes dividends quarterly, and currently yields roughly 1.5 % annualised. Sector weightings are dominated by Information Technology (≈ 23 %) and Health Care (≈ 13 %), making global tech earnings growth and demographic-driven healthcare spending the primary drivers of performance.
If you want a deeper, data-rich analysis of how UBU7’s risk-return profile compares to peers, a quick look at ValueRay’s interactive dashboard can help you surface the most relevant metrics.
What is the price of UBU7 shares?
Over the past week, the price has changed by +0.37%, over one month by -0.34%, over three months by +2.36% and over the past year by +4.31%.
Is UBU7 a buy, sell or hold?
What are the forecasts/targets for the UBU7 price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 128.5 | 33.5% |
UBU7 Fundamental Data Overview February 03, 2026
Revenue TTM = 0.0 EUR
EBIT TTM = 0.0 EUR
EBITDA TTM = 0.0 EUR
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.57b EUR (1.57b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 1.57b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 1.57b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 25.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 6.65% (E(1.57b)/V(1.57b) * Re(6.65%) + (debt-free company))
Discount Rate = 6.65% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)